GlassScriptPhysician profile
Brian M Chang
NPI 1700879343
$1,486.68
in general payments reported to CMS, 2019-2025
22 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $65.13 · 2021: $67.84 · 2022: $113 · 2023: $221 · 2024: $213 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $223.37 | 2019-2025 | Bromsite, Cequa, Xelpros |
| Aerie Pharmaceuticals, INC. | $179.30 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $132.48 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.76 | 2019 | |
| Horizon Therapeutics Plc | $89.98 | 2022-2023 | Tepezza |
| Glaukos Corporation | $74.60 | 2023-2025 | Idosetr, Idose |
| Bausch & Lomb Americas INC. | $72.37 | 2023-2025 | Miebo, Vyzulta |
| Abbvie INC. | $67.57 | 2023-2024 | Vuity, Alphagan P, Lumigan |
| Alcon Vision LLC | $60.55 | 2019-2024 | Rocklatan |
| Tarsus Pharmaceuticals, INC. | $58.63 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $51.17 | 2023-2025 | Dextenza |
| Allergan, INC. | $49.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.45 | 2019 | |
| Kala Pharmaceuticals, INC. | $39.82 | 2019-2021 | |
| Amgen INC. | $39.44 | 2024 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $32.92 | 2022-2025 | Oxervate |
| Genmab U.S., INC. | $32.27 | 2024 | Tivdak |
| Mallinckrodt Hospital Products INC. | $25.10 | 2024 | Acthar |
| Rxsight INC | $23.58 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $22.93 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Iridex Corporation | $19.98 | 2019 | |
| Oyster Point Pharma, INC. | $17.49 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.